P450 3A activity and cyclosporine dosing in kidney and heart transplant recipients

[1]  T. Annesley,et al.  Erythromycin breath test predicts oral clearance of cyclosporine in kidney transplant recipients , 1992, Clinical pharmacology and therapeutics.

[2]  J. Kolars,et al.  Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. , 1992, The Journal of clinical investigation.

[3]  P. Watkins.  Role of Cytochromes P45O in Drug Metabolism and Hepatotoxicity , 1990, Seminars in liver disease.

[4]  P. Maurel,et al.  Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[5]  J. Kolars,et al.  The erythromycin breath test as a predictor of cyclosporine blood levels , 1990, Clinical pharmacology and therapeutics.

[6]  T. Aoyama,et al.  Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. , 1989, The Journal of biological chemistry.

[7]  J. Derancourt,et al.  Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. , 1989, Drug metabolism and disposition: the biological fate of chemicals.

[8]  P. Watkins,et al.  Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. , 1989, The Journal of clinical investigation.

[9]  B. Kahan,et al.  Optimization of cyclosporine therapy in renal transplantation by a pharmacokinetic strategy. , 1988, Transplantation.

[10]  T. Kronbach,et al.  Cyclosporine metabolism in human liver: Identification of a cytochrome P‐450III gene family as the major cyclosporine‐metabolizing enzyme explains interactions of cyclosporine with other drugs , 1988, Clinical pharmacology and therapeutics.

[11]  G. Forbes,et al.  Central Nervous System Toxicity after Liver Transplantation , 1987 .

[12]  P. Watkins,et al.  Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. , 1987, The Journal of clinical investigation.

[13]  T. Annesley,et al.  Liquid-chromatographic analysis for cyclosporine with use of a microbore column and small sample volume. , 1986, Clinical chemistry.

[14]  D. Waxman,et al.  Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. , 1986, The Journal of biological chemistry.

[15]  C. V. van Buren,et al.  DEMOGRAPHIC FACTORS AFFECTING THE PHARMACOKINETICS OF CYCLOSPORINE ESTIMATED BY RADIOIMMUNOASSAY , 1986, Transplantation.

[16]  P. Watkins,et al.  Identification of an inducible form of cytochrome P-450 in human liver. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. D. Shoop,et al.  Test for alcoholic cirrhosis by conversion of [14C]- or [13C]galactose to expired CO2. , 1976, Gastroenterology.

[18]  M. J. Coon,et al.  The P450 superfamily: update on new sequences, gene mapping, accession numbers, early trivial names of enzymes, and nomenclature. , 1993, DNA and cell biology.

[19]  F. Guengerich.  Characterization of human microsomal cytochrome P-450 enzymes. , 1989, Annual review of pharmacology and toxicology.